Aclaris Therapeutics, Inc.
ACRS Nasdaq
SEC CIK 1557746
Follow Aclaris Therapeutics
Weekly email: filings, results
Revenue, last quarter
$1.5M
−55.1% vs same quarter last year
Net income
−$18.5M
−26.7% vs same quarter last year
EPS, diluted
−$0.12
+0% vs same quarter last year
Operating cash flow
−$24.1M
−120.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $7.8M | −$64.9M |
| FY24 | $18.7M | −$132.1M |
| FY23 | $31.2M | −$88.5M |
| FY22 | $29.8M | −$86.9M |
| FY21 | $6.8M | −$90.9M |
| FY20 | $6.5M | −$51M |
| FY19 | $4.2M | −$161.4M |
| FY18 | $6.2M | −$132.7M |
| FY17 | $1.7M | −$68.5M |
| FY16 | - | −$48.1M |
| FY15 | - | −$20.6M |
| FY14 | - | −$8.5M |
| FY13 | - | −$5.2M |
| FY12 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 73.3% | −975.9% | −829.6% |
| FY24 | 85.1% | −758.2% | −705.5% |
| FY23 | 89% | −311.6% | −283.1% |
| FY22 | 86.5% | −302% | −292.1% |
| FY21 | 30.3% | −1327.1% | −1344% |
| FY20 | 20.8% | −785.4% | −787% |
| FY19 | 4.1% | −2627.3% | −3817.2% |
| FY18 | 52.7% | −1378.3% | −2158% |
| FY17 | 28.3% | −3230% | −4071.5% |
| FY16 | - | - | - |
| FY15 | - | - | - |
| FY14 | - | - | - |
| FY13 | - | - | - |
| FY12 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$47.2M |
| FY24 | −$20.2M |
| FY23 | −$79.6M |
| FY22 | −$68.2M |
| FY21 | −$52.4M |
| FY20 | −$39.1M |
| FY19 | −$98.1M |
| FY18 | −$102.2M |
| FY17 | −$55.9M |
| FY16 | −$34.8M |
| FY15 | −$20.9M |
| FY14 | −$8.1M |
| FY13 | - |
| FY12 | - |
- Aclaris Therapeutics
- Healthcare median
Show the numbers
| Year | Aclaris Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −829.6% | −30.6% |
| FY24 | −705.5% | −47% |
| FY23 | −283.1% | −58% |
| FY22 | −292.1% | −80.4% |
| FY21 | −1344% | −71.8% |
| FY20 | −787% | −62.2% |
| FY19 | −3817.2% | −46.2% |
| FY18 | −2158% | −49.6% |
| FY17 | −4071.5% | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |